Plexium
- Founded: 2018
- Location: San Diego, CA
- Employee range: 50 - 200
- Clinical stage: RD
- Therapy area: Immuno-oncology
- Drug types: ONC, NEU
- Lead product: Undisclosed
- Product link: https://www.plexium.com/therapeutic-areas-plexium-e3-ligase-drugs/
- Funding: $102M B Feb 2022; $35M A Jan 2021; $28M A Oct 2019
- Investors: Column Group, DCVC Bio, M Ventures, CRV, Neotribe Ventures
plexium.com linkedin.com job board
Short description:
Small Molecules Targeting E3 Ligase
Drug notes:
7* additional undisclosed programs RD multiple cancers, CNS condition, undisclosed
Long description:
Plexium is advancing developments in targeted protein degradation (TPD). By using their proprietary ultra-high-throughput cell-based (uHTS) screening technology, Plexium is detecting and designing monovalent protein degraders that can be used in many modalities. The assay directly measures degradation of multiple target proteins in disease-relevant environments to identify hit compounds. The uHTS screening is part of the larger Plexium Platform that combines genomic analysis, computational modeling and AI analytics to create their TPD drugs.The monovalent protein degraders overcome the limitations of current approaches and include the discovery of novel E3 ligases and new molecular glues. Plexium is creating a diverse pipeline that is currently in preclinical stages.
Jobs:
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com